Severe Acute Respiratory Syndrome Coronavirus 2 Is Detected in the Gastrointestinal Tract of Asymptomatic Endoscopy Patients but Is Unlikely to Pose a Significant Risk to Healthcare Personnel.
COVID-19, coronavirus disease 2019
Colonic Liquid
E gene, envelope gene
Endoscopy
GI, gastrointestinal
N gene, nucleocapsid gene
NP, nucleocapsid protein
PFU, plaque-forming units
SARS-CoV-2
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Transmission Risk
qRT-PCR, quantitative reverse transcription polymerase chain reaction
Journal
Gastro hep advances
ISSN: 2772-5723
Titre abrégé: Gastro Hep Adv
Pays: Netherlands
ID NLM: 9918350485906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
03
2022
accepted:
03
06
2022
pubmed:
30
6
2022
medline:
30
6
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
Recent evidence suggests that the gut is an additional target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, whether SARS-CoV-2 spreads via gastrointestinal secretions remains unclear. To determine the prevalence of gastrointestinal SARS-CoV-2 infection in asymptomatic subjects, we analyzed gastrointestinal biopsy and liquid samples from endoscopy patients for the presence of SARS-CoV-2. We enrolled 100 endoscopic patients without known SARS-CoV-2 infection (cohort A) and 12 patients with a previous COVID-19 diagnosis (cohort B) in a cohort study performed at a regional hospital. Gastrointestinal biopsies and fluids were screened for SARS-CoV-2 by polymerase chain reaction (PCR), immunohistochemistry, and virus isolation assay, and the stability of SARS-CoV-2 in gastrointestinal liquids in vitro was analyzed. SARS-CoV-2 ribonucleic acid was detected by PCR in the colonic tissue of 1/100 patients in cohort A. In cohort B, 3 colonic liquid samples tested positive for SARS-CoV-2 by PCR and viral nucleocapsid protein was detected in the epithelium of the respective biopsy samples. However, no infectious virions were recovered from any samples. In vitro exposure of SARS-CoV-2 to colonic liquid led to a 4-log-fold reduction of infectious SARS-CoV-2 within 1 hour ( Overall, the persistent detection of SARS-CoV-2 in endoscopy samples after resolution of COVID-19 points to the gut as a long-term reservoir for SARS-CoV-2. Since no infectious virions were recovered and SARS-CoV-2 was rapidly inactivated in the presence of colon liquids, it is unlikely that performing endoscopic procedures is associated with a significant infection risk due to undiagnosed asymptomatic or persistent gastrointestinal SARS-CoV-2 infections.
Sections du résumé
Background and Aims
UNASSIGNED
Recent evidence suggests that the gut is an additional target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, whether SARS-CoV-2 spreads via gastrointestinal secretions remains unclear. To determine the prevalence of gastrointestinal SARS-CoV-2 infection in asymptomatic subjects, we analyzed gastrointestinal biopsy and liquid samples from endoscopy patients for the presence of SARS-CoV-2.
Methods
UNASSIGNED
We enrolled 100 endoscopic patients without known SARS-CoV-2 infection (cohort A) and 12 patients with a previous COVID-19 diagnosis (cohort B) in a cohort study performed at a regional hospital. Gastrointestinal biopsies and fluids were screened for SARS-CoV-2 by polymerase chain reaction (PCR), immunohistochemistry, and virus isolation assay, and the stability of SARS-CoV-2 in gastrointestinal liquids in vitro was analyzed.
Results
UNASSIGNED
SARS-CoV-2 ribonucleic acid was detected by PCR in the colonic tissue of 1/100 patients in cohort A. In cohort B, 3 colonic liquid samples tested positive for SARS-CoV-2 by PCR and viral nucleocapsid protein was detected in the epithelium of the respective biopsy samples. However, no infectious virions were recovered from any samples. In vitro exposure of SARS-CoV-2 to colonic liquid led to a 4-log-fold reduction of infectious SARS-CoV-2 within 1 hour (
Conclusion
UNASSIGNED
Overall, the persistent detection of SARS-CoV-2 in endoscopy samples after resolution of COVID-19 points to the gut as a long-term reservoir for SARS-CoV-2. Since no infectious virions were recovered and SARS-CoV-2 was rapidly inactivated in the presence of colon liquids, it is unlikely that performing endoscopic procedures is associated with a significant infection risk due to undiagnosed asymptomatic or persistent gastrointestinal SARS-CoV-2 infections.
Identifiants
pubmed: 35765598
doi: 10.1016/j.gastha.2022.06.002
pii: S2772-5723(22)00097-8
pmc: PMC9225937
doi:
Types de publication
Journal Article
Langues
eng
Pagination
844-852Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM134867
Pays : United States
Organisme : NIBIB NIH HHS
ID : U01 EB029242
Pays : United States
Informations de copyright
© 2022 Published by Elsevier Inc. on behalf of the AGA Institute.
Références
Gut. 1988 Aug;29(8):1035-41
pubmed: 3410329
Nat Commun. 2021 Nov 16;12(1):6610
pubmed: 34785679
Mucosal Immunol. 2021 Nov;14(6):1381-1392
pubmed: 34420043
Gut. 2022 Jan;71(1):226-229
pubmed: 34083386
Gastroenterol Hepatol. 2022 Jan 22;:
pubmed: 35077722
Am J Gastroenterol. 2021 Jan 1;116(1):202-205
pubmed: 33079747
Gastroenterology. 2021 Jun;160(7):2435-2450.e34
pubmed: 33676971
Nat Med. 2020 Jul;26(7):1077-1083
pubmed: 32405028
J Med Virol. 2021 Oct;93(10):5917-5923
pubmed: 34139026
Am J Gastroenterol. 2021 Feb 1;116(2):433-434
pubmed: 33038127
Viruses. 2021 Dec 23;14(1):
pubmed: 35062227
Gastroenterology. 2021 Nov;161(5):1702-1704.e3
pubmed: 34280387
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Cell Rep. 2021 Jun 1;35(9):109197
pubmed: 34043946
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Cell Rep. 2020 Jul 7;32(1):107863
pubmed: 32610043
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
J Med Virol. 2022 Apr;94(4):1255-1256
pubmed: 34850421
Pediatr Infect Dis J. 2020 Sep;39(9):e249-e256
pubmed: 32618932
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Gut. 2020 Jun;69(6):997-1001
pubmed: 32241899
Gastroenterology. 2021 Sep;161(3):1011-1029.e11
pubmed: 34029569
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Mol Syst Biol. 2021 Apr;17(4):e10232
pubmed: 33904651
Commun Biol. 2021 Nov 30;4(1):1343
pubmed: 34848826
Cell Rep Med. 2020 Sep 22;1(6):100098
pubmed: 32904687
Front Public Health. 2020 Nov 23;8:590041
pubmed: 33330334
Clin Infect Dis. 2021 Aug 2;73(3):361-366
pubmed: 32638022
Gastroenterology. 2022 May 1;:
pubmed: 35508284